Tag: Novartis

Novartis to spinoff Alcon into a standalone entity
Global

Novartis to spinoff Alcon into a standalone entity

Novartis said will spinoff Alcon, its eye care division, into a separately-traded standalone company. The planned spinoff would enable Novartis and Alcon to focus fully on their respective growth strategies. Completion of the transaction is subject to general market conditions, tax rulings and opinions, final Board of Directors endorsement and […]

Shannon Klinger to head legal unit at Novartis
Global

Shannon Klinger to head legal unit at Novartis

Pharmaceutical giant, Novartis said it has appointed Shannon Klinger as its Group General Counsel. The appointment of Shannon Klinger is as a result of the exit of Felix R. Ehrat, Group General Counsel of Novartis, who has decided to retire from the company. Mr. Ehrat said: “Although the contract was […]

Novartis acquires AveXis for $8.7 billion
Europe Global

Novartis acquires AveXis for $8.7 billion

Novartis announced has entered into an agreement and plan of merger with AveXis, Inc. to acquire the US-based Nasdaq-listed clinical-stage gene therapy company for USD 218 per share or a total of USD 8.7 billion in cash. The transaction was unanimously approved by the Boards of both companies. AveXis has […]

Bruno Strigini, Novartis’ head of oncology to retire
Global

Bruno Strigini, Novartis’ head of oncology to retire

Novartis said Bruno Strigini, CEO Novartis Oncology has decided to retire from Novartis and the industry for personal reasons. Joseph Jimenez, CEO of Novartis, said: “I’d like to thank Bruno Strigini for his contributions and achievements. He has navigated the business unit through the GleevecĀ® patent expiration and has led […]

Novartis gets approval for Rydapt, a drug for tough cancers
Global

Novartis gets approval for Rydapt, a drug for tough cancers

Novartis said the European Commission has approved Rydapt for two indications in rare, hard-to-treat cancers. The company said Rydapt is approved for use in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for […]